HSE struggling to identify candidates for vaccine boosters
Tens of thousands of immunocompromised people need a third Covid vaccine dose, but the lack of a register makes identifying them difficult
The HSE is struggling to identify immunocompromised individuals who require a third vaccine shot in order to be fully vaccinated against Covid-19.
To date, approximately 22,500 patients eligible for booster shots have been identified via hospital records, with 12,000 receiving appointments and 4,000 receiving a third MRNA dose since last Monday.
But the HSE estimates that up to five times those identified may need a third shot as part of the required vaccination protocol.
Subscribe from just €1 for the first month!
With any subscription you will have access to
Unlimited multi-device access to our iPad, iPhone and Android Apps
Unlimited access to our eReader library
Exclusive daily insight and opinion seven days a week
Create alerts to never miss a subject that matters to you
Get access to exclusive offers for subscribers on gifts and experiences
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine
Government hopes to raise vaccination rates via passports for pubs and restaurants
Ministers hope that extending the use of vaccination passports beyond the planned date of October 22 will put pressure on more unvaccinated people to get the jab
The Last Post: Covid symptoms ‘drink-driving’ comparison is an analogy too far
Professor Philip Nolan of Nphet said ‘leaving your home with symptoms has to become socially unacceptable, like drink-driving’, but comparing people with allergies or head colds to people who drink and then get behind the wheel is over the top
Full vaccination more effective than a booster campaign, Nphet advisor says
Cathal Walsh says strain-specific top-ups can play a role but primary vaccination is still far more effective
Covid-19: Wonder drugs become another weapon in ongoing battle against the virus
Recent tests by Merck of an antiviral pill that appears to cut hospitalisation risk by 50 per cent sent the company’s shares soaring. Other companies, including Dublin-based AiPharma, are also in the race to develop antiviral medications